University of Western Australia

www.uwa.edu.au/
Perth, Australia

The University of Western Australia is a research-intensive university in Perth, Australia that was established by an act of the Western Australian Parliament in February 1911, and began teaching students for the first time in 1913. It is the oldest university in the state of Western Australia and is colloquially known as a "sandstone university". It is also a member of the Group of Eight.UWA was established under and is governed by the University of Western Australia Act 1911. The Act provides for control and management by the university's Senate, and gives it the authority, amongst other things, to make statutes, regulations and by-laws, details of which are contained in the university Calendar.UWA is highly ranked internationally in various publications: the 2013/14 QS World University Rankings placed UWA at 84th internationally, and in August 2014 the The Academic Ranking of World Universities from Shanghai Jiao Tong University placed the university at 88th in the world. To date, the university has produced 100 Rhodes Scholars, 1 Nobel Prize laureate and 1 Australian Prime Minister graduated from UWA.UWA recently joined the Matariki Network of Universities as the youngest member, the only one established during the 20th century. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Research Institute At Nationwide Childrens Hospital and University of Western Australia | Date: 2015-08-07

The present invention relates to the delivery of oligomers for treating patients with a 5 mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5 mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.


Patent
University of Western Australia and Telethon Kids Institute | Date: 2015-07-31

This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.


Patent
University of Western Australia | Date: 2017-07-26

Provided herein are methods for modulating tumour stroma, normalizing tumour vasculature and/or improving vascular function in a tumour, comprising exposing a tumour to an effective amount of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide. Also provided are methods for treating tumours and increasing the survival time of tumour-bearing patients, comprising administering an effective amount of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide. Also provided are methods for treating tumours and extending survival of tumour-bearing patients comprising administering an effective amount of a peptide-protein conjugate comprising a LIGHT polypeptide and a tumour homing peptide in combination with one or more immunotherapeutic agents.


Patent
University of Western Australia and Telethon Kids Institute | Date: 2017-07-26

This invention relates to systems and methods for evaluating the differentiality of a set of discrete random variables between two or more conditions, such as a malignant condition responding to treatment regime and one that is not. It also provides for the identification and selection of drugs that act in coordinated manner to phenocopy a genetic network of a malignant condition that responds to at least an immune checkpoint blockade agent.


Patent
University of Western Australia | Date: 2017-01-25

A recombinant polypeptide is described which comprises at least one PUF RNA-binding domain capable of specifically binding to a cytosine RNA base. The PUF RNA-binding domain of the polypeptide comprises at least one RNA base-binding motif of the general formula X_(1)X_(2)X_(3)X_(4)X_(5)X_(6)X_(7)X_(8)X_(9)X_(10)X_(11 )wherein X_(1 )is selected from the group including glutamine (Q), valine (V), methionine (M), proline (P), glutamic acid (E), and lysine (K); X_(2 )is selected from the group including histidine (H), phenylalanine (F), tyrosine (Y), and asparagine (N); X_(3 )is selected from the group including glycine (G) and alanine (A); X_(4 )is selected from the group including glycine (G), alanine (A), serine (S), threonine (T) and cysteine (C); X_(5 )is selected from the group including arginine (R), tyrosine (Y), histidine (H), and asparagine (N); X_(6 )is selected from the group including phenylalanine (F), leucine (L), and valine (V); X_(7 )is selected from the group including isoleucine (I), leucine (L), and valine (V); X_(8 )is arginine (R); X_(9 )is selected from the group including leucine (L), lysine (K), arginine (R), glutamine (Q), and histidine (H); X_(10 )is selected from the group including lysine (K), phenylalanine (F), alanine (A), cysteine (C), isoleucine (I), valine (V), leucine (L), and methionine (M); and X_(11 )is selected from the group including leucine (L), phenylalanine (F), isoleucine (I), and valine (V); and wherein the RNA base-binding motif is operably capable of specifically binding to a cytosine RNA base.


Patent
Proteomics International Pty Ltd and University of Western Australia | Date: 2017-04-05

The invention provides biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement Clq subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.


Patent
The Research Institute At Nationwide Childrens Hospital and University of Western Australia | Date: 2017-06-21

The present invention relates to the delivery of oligomers for treating patients with a 5 mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5 mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy.


Patent
University of Western Australia | Date: 2017-10-11

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.


Patent
University of Western Australia | Date: 2017-10-04

The present disclosure provides a device for evaluating a mechanical property of a material, in particular the Youngs or elastic modulus. The device comprises a sensing layer that has a contact surface for contacting a surface area of the material. The sensing layer has a property or dimension that is pressure sensitive. The device also comprises a detector arranged to detect electromagnetic radiation that propagates through at least the sensing layer. The device is arranged such that, when the contact surface of the sensing layer is in contact with the surface area of the material and a load is applied on at least a portion of the surface area of the material, the detected electromagnetic radiation can be used to determine stress within a portion of the sensing layer, the determined stress being indicative of the mechanical property of the material.


Long R.L.,University of Western Australia
Biological reviews of the Cambridge Philosophical Society | Year: 2015

Seed persistence is the survival of seeds in the environment once they have reached maturity. Seed persistence allows a species, population or genotype to survive long after the death of parent plants, thus distributing genetic diversity through time. The ability to predict seed persistence accurately is critical to inform long-term weed management and flora rehabilitation programs, as well as to allow a greater understanding of plant community dynamics. Indeed, each of the 420000 seed-bearing plant species has a unique set of seed characteristics that determine its propensity to develop a persistent soil seed bank. The duration of seed persistence varies among species and populations, and depends on the physical and physiological characteristics of seeds and how they are affected by the biotic and abiotic environment. An integrated understanding of the ecophysiological mechanisms of seed persistence is essential if we are to improve our ability to predict how long seeds can survive in soils, both now and under future climatic conditions. In this review we present an holistic overview of the seed, species, climate, soil, and other site factors that contribute mechanistically to seed persistence, incorporating physiological, biochemical and ecological perspectives. We focus on current knowledge of the seed and species traits that influence seed longevity under ex situ controlled storage conditions, and explore how this inherent longevity is moderated by changeable biotic and abiotic conditions in situ, both before and after seeds are dispersed. We argue that the persistence of a given seed population in any environment depends on its resistance to exiting the seed bank via germination or death, and on its exposure to environmental conditions that are conducive to those fates. By synthesising knowledge of how the environment affects seeds to determine when and how they leave the soil seed bank into a resistance-exposure model, we provide a new framework for developing experimental and modelling approaches to predict how long seeds will persist in a range of environments. © 2014 The Authors. Biological Reviews © 2014 Cambridge Philosophical Society.

Loading University of Western Australia collaborators
Loading University of Western Australia collaborators